<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00262678</url>
  </required_header>
  <id_info>
    <org_study_id>EN3267-005</org_study_id>
    <nct_id>NCT00262678</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Sublingual Fentanyl Tablets in Treatment of Breakthrough Pain in Cancer Patients.</brief_title>
  <official_title>A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of EN3267 for the Treatment of Breakthrough Pain in Opioid Tolerant Cancer Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prostrakan Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prostrakan Pharmaceuticals</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the effectiveness and safety of sublingual fentanyl&#xD;
      tablets in relieving breakthrough pain in cancer patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2005</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <condition>Pain</condition>
  <condition>Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EN3267</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Males or females 17 years of age or older&#xD;
&#xD;
          -  Stable cancer-related pain.&#xD;
&#xD;
          -  Are receiving a stable, fixed-schedule oral opioid regimen equivalent to 60 to 1000 mg&#xD;
             of oral morphine per day or transdermal fentanyl therapy equivalent to 50 to 300 Âµg/h,&#xD;
             and are on a stable dose of opioid medication for relief of breakthrough pain for at&#xD;
             least 14 days prior to screening.&#xD;
&#xD;
          -  Experiencing 1-4 episodes of breakthrough pain per day.&#xD;
&#xD;
          -  Meet the criteria defined in the Eastern Cooperative Oncology Group (ECOG) Performance&#xD;
             Status for Grade 0, 1, or 2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Are pregnant or lactating.&#xD;
&#xD;
          -  Have uncontrolled or rapidly escalating pain.&#xD;
&#xD;
          -  Have moderate to severe ulcerative mucositis.&#xD;
&#xD;
          -  Have a cardiopulmonary disease that would increase the risk of administering potent&#xD;
             opioids.&#xD;
&#xD;
          -  Have neurologic or psychologic disease that would compromise data collection&#xD;
&#xD;
          -  Have any clinically significant condition that would, in the investigator's opinion,&#xD;
             preclude study participation.&#xD;
&#xD;
          -  Are currently taking monoamine oxidase inhibitors (MAOIs), or have taken MAOIs within&#xD;
             14 days prior to enrolling in the study.&#xD;
&#xD;
          -  Have received strontium 89 therapy within 60 days prior to entering the study.&#xD;
&#xD;
          -  Have received anti-neoplastic therapy within 2 weeks of study entry that, in the&#xD;
             investigator's opinion, will influence assessment of breakthrough pain&#xD;
&#xD;
          -  Have received any investigational drug (non-approved) within 30 days prior to the&#xD;
             first dose of study medication, or are scheduled to receive an investigational drug&#xD;
             other than EN3267 during the course of the study.&#xD;
&#xD;
          -  Have hypersensitivities, allergies, or contraindications to fentanyl.&#xD;
&#xD;
          -  Have a significant prior history of substance abuse or alcohol abuse.&#xD;
&#xD;
          -  May have difficulty complying with the protocol, as assessed by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>17 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carolinas Pain Institute</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>December 6, 2005</study_first_submitted>
  <study_first_submitted_qc>December 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2005</study_first_posted>
  <last_update_submitted>June 2, 2009</last_update_submitted>
  <last_update_submitted_qc>June 2, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 4, 2009</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breakthrough Pain</mesh_term>
  </condition_browse>
  <pending_results>
    <submitted>January 24, 2014</submitted>
    <returned>March 13, 2014</returned>
    <submitted>March 10, 2020</submitted>
    <returned>March 23, 2020</returned>
    <submitted>September 18, 2020</submitted>
    <returned>October 12, 2020</returned>
    <submitted>December 3, 2020</submitted>
    <returned>December 29, 2020</returned>
    <submitted>March 15, 2021</submitted>
    <returned>April 7, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

